Seroprevalence of SARS-CoV-2 immunoglobulin G in HIV-positive and HIV-negative individuals in KwaZulu-Natal, South Africa.
KwaZulu-Natal
SARS-CoV-2 IgG prevalence
anti-SARS-CoV-2 IgG HIV-positive and negative
seroprevalence HIV-positive and HIV-negative
seroprevalence SARS-CoV-2 IgG
Journal
African journal of laboratory medicine
ISSN: 2225-2002
Titre abrégé: Afr J Lab Med
Pays: South Africa
ID NLM: 101603205
Informations de publication
Date de publication:
2023
2023
Historique:
received:
26
08
2022
accepted:
29
03
2023
medline:
12
7
2023
pubmed:
12
7
2023
entrez:
12
7
2023
Statut:
epublish
Résumé
KwaZulu-Natal ranked second highest among South African provinces for the number of laboratory-confirmed cases during the second wave of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. The seroprevalence of SARS-CoV-2 among certain vulnerable groups, such as people living with HIV in KwaZulu-Natal, is unknown. The study aimed to determine the prevalence of SARS-CoV-2 immunoglobulin G (IgG) in HIV-positive versus HIV-negative patients. This was a retrospective analysis of residual clinical blood specimens unrelated to coronavirus disease 2019 (COVID-19) submitted for diagnostic testing at Inkosi Albert Luthuli Central Hospital, Durban, from 10 November 2020 to 09 February 2021. Specimens were tested for SARS-CoV-2 immunoglobulin G on the Abbott Architect analyser. A total of 1977/8829 (22.4%) specimens were positive for SARS-CoV-2 antibodies. Seroprevalence varied between health districts from 16.4% to 37.3%, and was 19% in HIV-positive and 35.3% in HIV-negative specimens. Seroprevalence was higher among female patients (23.6% vs 19.8%; Our results highlight that during the second COVID-19 wave in KwaZulu-Natal a large proportion of people living with HIV were still immunologically susceptible. The reduced seropositivity in people with virological failure further emphasises the importance of targeted vaccination and vaccine response monitoring in these individuals. This study contributes to data on SARS-CoV-2 seroprevalence before and during the second wave in KwaZulu-Natal, South Africa, which has the highest HIV prevalence globally. Reduced seropositivity was found among people living with HIV with virological failure, highlighting the importance of targeted booster vaccination and vaccine response monitoring.
Sections du résumé
Background
UNASSIGNED
KwaZulu-Natal ranked second highest among South African provinces for the number of laboratory-confirmed cases during the second wave of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. The seroprevalence of SARS-CoV-2 among certain vulnerable groups, such as people living with HIV in KwaZulu-Natal, is unknown.
Objective
UNASSIGNED
The study aimed to determine the prevalence of SARS-CoV-2 immunoglobulin G (IgG) in HIV-positive versus HIV-negative patients.
Methods
UNASSIGNED
This was a retrospective analysis of residual clinical blood specimens unrelated to coronavirus disease 2019 (COVID-19) submitted for diagnostic testing at Inkosi Albert Luthuli Central Hospital, Durban, from 10 November 2020 to 09 February 2021. Specimens were tested for SARS-CoV-2 immunoglobulin G on the Abbott Architect analyser.
Results
UNASSIGNED
A total of 1977/8829 (22.4%) specimens were positive for SARS-CoV-2 antibodies. Seroprevalence varied between health districts from 16.4% to 37.3%, and was 19% in HIV-positive and 35.3% in HIV-negative specimens. Seroprevalence was higher among female patients (23.6% vs 19.8%;
Conclusion
UNASSIGNED
Our results highlight that during the second COVID-19 wave in KwaZulu-Natal a large proportion of people living with HIV were still immunologically susceptible. The reduced seropositivity in people with virological failure further emphasises the importance of targeted vaccination and vaccine response monitoring in these individuals.
What the study adds
UNASSIGNED
This study contributes to data on SARS-CoV-2 seroprevalence before and during the second wave in KwaZulu-Natal, South Africa, which has the highest HIV prevalence globally. Reduced seropositivity was found among people living with HIV with virological failure, highlighting the importance of targeted booster vaccination and vaccine response monitoring.
Identifiants
pubmed: 37434993
doi: 10.4102/ajlm.v12i1.2065
pii: AJLM-12-2065
pmc: PMC10331028
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2065Informations de copyright
© 2023. The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no financial or personal relationships that may have inappropriately influenced them in writing this article.
Références
S Afr Med J. 2020 Jul 17;110(9):842-845
pubmed: 32880264
Public Health Action. 2021 Jun 21;11(2):58-60
pubmed: 34159063
JAMA Intern Med. 2020 Jul 21;:
pubmed: 32692365
PLoS One. 2022 Feb 4;17(2):e0262442
pubmed: 35120133
BMJ. 2020 Sep 3;370:m3364
pubmed: 32883673
Emerg Infect Dis. 2021 Dec;27(12):3020-3029
pubmed: 34477548
J Virol. 2021 Jan 13;95(3):
pubmed: 33144321
Lancet HIV. 2021 Jun;8(6):e334-e341
pubmed: 33933189
Lancet HIV. 2021 May;8(5):e294-e305
pubmed: 33915101
Lancet Glob Health. 2021 Sep;9(9):e1216-e1225
pubmed: 34252381
EClinicalMedicine. 2021 Jun;36:100902
pubmed: 34056568
PLoS One. 2021 Apr 2;16(4):e0248946
pubmed: 33798211
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
S Afr Med J. 2021 Nov 05;111(11):1078-1083
pubmed: 34949273
Science. 2020 Dec 11;370(6522):1339-1343
pubmed: 33159009
N Engl J Med. 2020 Oct 29;383(18):1782-1784
pubmed: 32871061
J Infect. 2020 Dec;81(6):e10-e12
pubmed: 32961253
Nature. 2021 Apr;592(7854):438-443
pubmed: 33690265
Curr Opin HIV AIDS. 2021 Jan;16(1):63-73
pubmed: 33186229
Ann Intern Med. 2020 Sep 15;173(6):450-460
pubmed: 32496919
Lancet Glob Health. 2021 May;9(5):e598-e609
pubmed: 33705690
J Med Virol. 2022 Aug;94(8):3676-3684
pubmed: 35441368
Immunol Rev. 2017 Jan;275(1):33-48
pubmed: 28133792
AIDS. 2022 Mar 15;36(4):F1-F5
pubmed: 35013085
Int J Epidemiol. 2022 May 9;51(2):404-417
pubmed: 34718591
J Exp Med. 2020 Jun 1;217(6):
pubmed: 32353870
Clin Microbiol Infect. 2021 Mar;27(3):331-340
pubmed: 33228974
Emerg Infect Dis. 2021 Mar;27(3):928-931
pubmed: 33350923
AIDS. 2022 Mar 1;36(3):479-481
pubmed: 35084386